Abstract
A 13 year-old boy with Prader-Willi syndrome and steatohepatitis presented with diabetic ketoacidosis 4 weeks after the initiation of growth hormone (GH) treatment. He did not have signs or symptoms of type 2 diabetes mellitus (DM2) before the initiation of GH treatment. Hyperglycemia resolved 2 months after discontinuation of GH. He redeveloped DM2 6 months later associated with excessive weight gain. Diabetic ketoacidosis as a rare complication of GH therapy emphasizes the importance of screening for carbohydrate intolerance before and during GH treatment in patients with Prader-Willi syndrome. Steatohepatitis may be the only manifestation of insulin resistance and warrants further evaluation.
MeSH terms
-
Adolescent
-
Critical Care
-
Diabetes Mellitus, Type 2 / complications
-
Diabetes Mellitus, Type 2 / diagnosis
-
Diabetes Mellitus, Type 2 / therapy
-
Diabetic Ketoacidosis / chemically induced*
-
Diabetic Ketoacidosis / complications
-
Diabetic Ketoacidosis / diagnosis
-
Diet
-
Drug Administration Schedule
-
Fatty Liver / complications
-
Fatty Liver / diagnosis
-
Fatty Liver / drug therapy*
-
Forecasting
-
Growth Hormone / administration & dosage
-
Growth Hormone / adverse effects*
-
Growth Hormone / therapeutic use*
-
Hospitalization
-
Humans
-
Hypoglycemia / chemically induced
-
Hypoglycemia / complications
-
Insulin / therapeutic use
-
Male
-
Prader-Willi Syndrome / diagnosis
-
Prader-Willi Syndrome / drug therapy*
-
Prader-Willi Syndrome / genetics
-
Time Factors
-
Treatment Failure
-
Weight Gain